Invesco
ITCI

Invesco’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Invesco’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,066
Closed -$11.2M – 3917
2025
Q1 		$11.2M Sell
85,066
-2,992,108
-97% -$373M ﹤0.01% 1732
2024
Q4 		$257M Buy
3,077,174
+87,582
+3% +$7.2M 0.05% 514
2024
Q3 		$219M Buy
2,989,592
+52,238
+2% +$3.93M 0.04% 569
2024
Q2 		$201M Buy
2,937,354
+864,373
+42% +$59.9M 0.04% 568
2024
Q1 		$143M Buy
2,072,981
+109,324
+6% +$7.51M 0.03% 695
2023
Q4 		$141M Buy
1,963,657
+28,275
+1% +$1.63M 0.03% 662
2023
Q3 		$101M Sell
1,935,382
-39,499
-2% -$2.3M 0.03% 726
2023
Q2 		$125M Buy
1,974,881
+156,089
+9% +$9.73M 0.03% 645
2023
Q1 		$98.5M Buy
1,818,792
+42,761
+2% +$2.07M 0.03% 720
2022
Q4 		$94M Buy
1,776,031
+93,238
+6% +$4.67M 0.03% 729
2022
Q3 		$78.3M Buy
1,682,793
+866,606
+106% +$45.3M 0.03% 750
2022
Q2 		$46.6M Buy
816,187
+337,802
+71% +$19.2M 0.01% 944
2022
Q1 		$29.3M Buy
478,385
+445,945
+1,375% +$23.2M 0.01% 1266
2021
Q4 		$1.7M Sell
32,440
-1,757
-5% -$73.8K ﹤0.01% 2858
2021
Q3 		$1.27M Sell
34,197
-219,481
-87% -$7.63M ﹤0.01% 3012
2021
Q2 		$10.4M Sell
253,678
-49,496
-16% -$1.83M ﹤0.01% 2039
2021
Q1 		$10.3M Buy
303,174
+280,800
+1,255% +$9.74M ﹤0.01% 1929
2020
Q4 		$712K Sell
22,374
-237,998
-91% -$6.25M ﹤0.01% 3073
2020
Q3 		$6.68M Sell
260,372
-1,902
-0.7% -$43.4K ﹤0.01% 1863
2020
Q2 		$6.73M Sell
262,274
-31,265
-11% -$633K ﹤0.01% 1839
2020
Q1 		$4.51M Buy
293,539
+261,986
+830% +$5.69M ﹤0.01% 1952
2019
Q4 		$1.08M Sell
31,553
-3,492
-10% -$41.9K ﹤0.01% 2959
2019
Q3 		$261K Buy
35,045
+1,284
+4% +$12.3K ﹤0.01% 3470
2019
Q2 		$438K Buy
33,761
+2,060
+6% +$26.4K ﹤0.01% 3366
2019
Q1 		$386K Buy
31,701
+12,222
+63% +$156K ﹤0.01% 3402
2018
Q4 		$222K Sell
19,479
-802
-4% -$12.9K ﹤0.01% 3538
2018
Q3 		$440K Buy
20,281
+486
+2% +$10.2K ﹤0.01% 3477
2018
Q2 		$350K Sell
19,795
-16,826
-46% -$342K ﹤0.01% 3547
2018
Q1 		$771K Sell
36,621
-60,989
-62% -$1.19M ﹤0.01% 3152
2017
Q4 		$1.41M Buy
97,610
+51,414
+111% +$794K ﹤0.01% 2816
2017
Q3 		$729K Buy
46,196
+1,020
+2% +$15K ﹤0.01% 3164
2017
Q2 		$561K Buy
45,176
+17,455
+63% +$202K ﹤0.01% 3292
2017
Q1 		$450K Buy
+27,721
New +$401K ﹤0.01% 3378
2016
Q2 		– Sell
-66,475
Closed -$1.85M – 3727
2016
Q1 		$1.85M Sell
66,475
-70,400
-51% -$2.35M ﹤0.01% 2516
2015
Q4 		$7.36M Buy
136,875
+6,486
+5% +$327K ﹤0.01% 1629
2015
Q3 		$5.22M Buy
130,389
+128,064
+5,508% +$4.18M ﹤0.01% 1852
2015
Q2 		$74K Buy
+2,325
New +$59K ﹤0.01% 3926

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Invesco's ITCI Position: Q2 2025 in Review

Invesco sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 85,066 shares — an estimated $11.2M sold.

Invesco first reported a position in ITCI in Q2 2015 and held it in 37 quarters. The position peaked at $257M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Invesco reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 85,066 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $11.2M.
  • Invesco first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 37 quarters.
  • Invesco's Intra-Cellular Therapies Inc. position peaked at $257M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.